LOGIN
ID
PW
MemberShip
2023-09-24 07:04
All News
Policy
Company
Product
Opinion
InterView
검색
Dailypharm Live Search
Close
Roche 2018 Annualreport
Roche 2018 Annualreport
2019-12-23
NOVARTIS 2018 Annualreport
NOVARTIS 2018 Annualreport
2019-12-23
2018 Multinational Pharma Sales
2018 Multinational Pharma Sales
2019-11-15
Risk-Sharing Agreements in the EU: A Systematic Review
Risk-Sharing Agreements in the EU: A Systematic Review of Major Trends
2019-11-15
Managed Entry Agreements for
Managed Entry Agreements for Oncology Drugs
2019-11-15
OPINION
[Reporter’s View] Biobetters to prosper with better prices
Reporter's view |
Eo, Yun-Ho
[Reporter’s View] Industry suffers from ‘Re-eval Neurosis'
Reporter's view |
Kim, Jin-Gu
[Reporter’s View] MFDS makes changes ahead PIC/S reeval
Reporter's view |
Lee, Hye-Kyung
INTERVIEW
‘Leclaza can occupy 50% of mkt if used as combination'
Professor Byoung-Chul Cho, Professor Ki Hyeong Lee
Immunotherapy for early lung cancer was used
"5 out of 7 cases showed CR"
The use of HTN combi tx in Korea is the highest in the world
‘Even a 0.2 vision is a miracle to some’
Samsung Bio, investing in Swiss ADC bio company
Data
Roche 2018 Annualreport
Roche 2018 Annualreport
NOVARTIS 2018 Annualreport
NOVARTIS 2018 Annualreport
2018 Multinational Pharma Sales
2018 Multinational Pharma Sales
MOST READ
1
nAMD drug Vabysmo will likely be listed for reimb in Oct
2
Reimbursement imminent for some anticancer drugs in KOR
3
A new drug for optic shylomyelitis is necessary
4
Korea United Pharm signs export agreement with Vietnam TAK
5
[Reporter’s View] Industry suffers from ‘Re-eval Neurosis'
6
The NHIS begins negotiations to increase the size of PSE
7
Olumiant re-examination period extended by 35 months
8
KRW 100 bil loxoprofen market suffers reimb cuts
9
MFDS starts review on phenylephrine after FDA advisory decis
10
Authorization rate for No.16 is still 0%
